The modern era has dawned! At breakneck speed, artificial intelligence models are penetrating all sectors of the economy. Business models that worked yesterday are disappearing from the market or being replaced by new ones. Data analysis now happens at lightning speed, with knowledge built over hundreds of years. The pharmaceutical industry is increasingly using artificial intelligence to make clinical trials more efficient and precise. AI is particularly effective in analyzing large amounts of medical data, recognizing patterns, and optimizing decision-making processes. The improvements in evaluation and interpretation are revolutionary. The Canadian technology company NetraMark Holdings Inc. (WKN: A3D5X9 | ISIN: CA64119M1059 | Ticker symbol: AIAI) is developing solutions for the pharmaceutical industry to use Generative Artificial Intelligence (Gen AI). The results so far indicate a quantum leap. Meanwhile, NetraMark's market value is still in its infancy. Time is of the essence!Den vollständigen Artikel lesen ...
© 2025 researchanalyst.com (EN)
